Trifecta Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Trifecta Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.8K	Hold	245	–	–	0.01%	199
2026 Q1	$31.3K	Hold	245	–	–	﹤0.01%	192
2025 Q4	$29.9K	Hold	245	–	–	﹤0.01%	183
2025 Q3	$24.5K	Hold	245	–	–	﹤0.01%	198
2025 Q2	$20.3K	Hold	245	–	–	﹤0.01%	216
2025 Q1	$19.9K	Hold	245	–	–	﹤0.01%	186
2024 Q4	$22.1K	Hold	245	–	–	﹤0.01%	185
2024 Q3	$24.2K	Hold	245	–	–	0.01%	178
2024 Q2	$22.7K	Hold	245	–	–	0.01%	181
2024 Q1	$23.2K	Hold	245	–	–	0.01%	170
2023 Q4	$21.9K	Hold	245	–	–	0.01%	170
2023 Q3	$17.9K	Hold	245	–	–	0.01%	183
2023 Q2	$20.4K	Hold	245	–	–	0.01%	181
2023 Q1	$18.7K	Hold	245	–	–	0.01%	188
2022 Q4	$20.3K	Buy	+245	New	+$19.8K	0.01%	172

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Trifecta Capital Advisors's XBI Position: Q2 2026 in Review

Trifecta Capital Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 245 shares worth $38.8K. The position accounts for 0.01% of the portfolio, ranked #199.

Trifecta Capital Advisors first reported a position in XBI in Q4 2022 and has held it in 15 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Trifecta Capital Advisors held 245 shares of State Street SPDR S&P Biotech ETF worth $38.8K as of Q2 2026.
Trifecta Capital Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #199 holding.
Trifecta Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and has held it in 15 quarters since.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.